CombiMatrix teams with RationalDiagnostics

Sept. 15, 2003 — CombiMatrix Corp. has teamed up with two University of Washington researchers and their clinical genomics firm to develop a microarray-based test for lymphoma diagnosis, according to a news release.

CombiMatrix, an operating group of Newport Beach, Calif.-based Acacia Research Corp., is providing customizable microarrays for nucleic acid-based diagnostic tests being developed by Daniel Sabath and Stephen Schmechel. The researchers have identified genes whose expression patterns can distinguish various lymphoma types, and seek to develop microarrays for detection and prediction of clinical outcome, the release said.

CombiMatrix also is collaborating on research with RationalDiagnostics, co-founded by Sabath and Schmechel. The Seattle-based firm is developing diagnostic tools based on the discovery of disease-specific genes.

CombiMatrix, which trades on Nasdaq, closed Friday at 4.40, up from 4.00 Thursday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.